Evaluation and management of ketosis-prone diabetes

References

• Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–149.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Nalini R, Hampe C, et al. Syndromes of ketosis prone diabetes mellitus. Endo Rev. 2008;29:292–302.
   PubMed Web of Science ®Google Scholar
• Winter WE, Maclaren NK, Riley WJ, et al. Maturity-onset diabetes of youth in black Americans. N Engl J Med. 1987 Feb 5;316:285–291.
   PubMed Web of Science ®Google Scholar
• Banerji MA, Chaiken RL, Huey H, et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes. Diabetes. 1994 Jun;43:741–745.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Casals MM, Gebhart SP, et al. Diabetic ketoacidosis in obese African-Americans. Diabetes. 1995 Jul;44:790–795.
   PubMed Web of Science ®Google Scholar
• Aizawa T, Katakura M, Taguchi N, et al. Ketoacidosis-onset noninsulin dependent diabetes in Japanese subjects. Am J Med Sci. 1995;310:198–201.
   PubMed Web of Science ®Google Scholar
• Wilson C, Krakoff J, Gohdes D. Ketoacidosis in Apache Indians with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997 Oct;13(157):2098–2100.
   Google Scholar
• Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care. 1997 Apr;20:484–486.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Zern JW, Hyman DJ, et al. New profiles of diabetic ketoacidosis: type 1 vs type 2 diabetes and the effect of ethnicity. Arch Intern Med. 1999 Oct 25;159:2317–2322.
   PubMed Web of Science ®Google Scholar
• Westphal SA. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. Am J Med. 1996 Jul;101:19–24.
   PubMed Web of Science ®Google Scholar
• Maldonado M, Hampe CS, Gaur LK, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab. 2003;88(11):5090–5098.
   PubMed Web of Science ®Google Scholar
• Pinto ME, Villena JE, Villena AE. Diabetic ketoacidosis in Peruvian patients with type 2 diabetes mellitus. Endo Prac. 2008;14:442–446.
   Google Scholar
• Wang ZH, Kihl-Selstam E, Eriksson JW. Ketoacidosis occurs in both type 1 and type 2 diabetes – a population-based study from Northern Sweden. Diabet Med. 2008 Jul;25:867–870.
   PubMed Web of Science ®Google Scholar
• Jabbar A, Farooqui K, Habib A, et al. Clinical characteristics and outcomes of diabetic ketoacidosis in Pakistani adults with type 2 diabetes mellitus. Diabet Med. 2004;21:920–923.
   PubMed Web of Science ®Google Scholar
• Yamada K, Nokada K. Diabetic ketoacidosis in young obese Japanese men. Diabetes Care. 1996 Jun;19:671.
   PubMed Web of Science ®Google Scholar
• Gupta P, Liu Y, Lapointe M, et al. Changes in circulating adiponectin, leptin, glucose and C-peptide in patients with ketosis-prone diabetes. Diabet Med. 2015;32:692–700.
   PubMedGoogle Scholar
• Kim MK, Lee SH, Kim JH, et al. Clinical characteristics of Korean patients with new-onset diabetes presenting with diabetic ketoacidosis. Diabetes Res Clin Pract. 2009;85:e8–e11.
   PubMedGoogle Scholar
• Liu B, Yu C, Li Q, et al. Ketosis-onset diabetes and ketosis-prone diabetes: same or not? Int J Endocrinol. 2013;2013:821403.
   PubMedGoogle Scholar
• Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006 Mar 7;144:350–357.
   PubMed Web of Science ®Google Scholar
• Redondo MJ, Rodriguez LM, Escalante M, et al. Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis. Pediatr Diabetes. 2013;14:333–340.
   PubMed Web of Science ®Google Scholar
• Brooks-Worrell BM, Iyer D, Coraza I, et al. Islet-specific T-cell responses and proinflammatory monocytes define subtypes of autoantibody- negative ketosis-prone diabetes. Diabetes Care. 2013;36:4098–4103.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Garza G, Rodriguez L, et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care. 2006 Dec;29:2575–2579.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Sobngwi E, Porcher R, et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes. 2004;53:645–653.
   PubMedGoogle Scholar
• Nalini R, Ozer K, Maldonado M, et al. Presence or absence of a known diabetic ketoacidosis precipitant defines distinct syndromes of “A-β+” ketosis-prone diabetes based on long-term β-cell function, human leukocyte antigen class II alleles, and sex predilection. Metabolism. 2010;59:1448–1455.
   PubMed Web of Science ®Google Scholar
• Smiley D, Chandra P, Umpierrez GE. Update on diagnosis, pathogenesis and management of ketosis-prone type 2 diabetes mellitus. Diabetes Manag (Lond). 2011 Nov 1;1:589–600.
   PubMedGoogle Scholar
• Mauvais-Jarvis F, Smith SB, Le May C, et al. PAX4 gene variations predispose to ketosis-prone diabetes. Hum Mol Genet. 2004 Dec 15;13(24):3151–3159. Epub 2004 Oct 27.
   PubMed Web of Science ®Google Scholar
• Ling Z, De Pauw P, Jacobs-Tulleneers-Thevissen D, et al. Plasma GAD65, a marker for early β-cell loss after intraportal islet cell transplantation in diabetic patients. J Clin Endocrinol Metab. 2015;100:2314–2321.
   PubMed Web of Science ®Google Scholar
• National Hospital Discharge Survey. Centers for disease control and prevention. 2015. Web. 18 May 2018.
   Google Scholar
• Kitabchi AE, Umpierrez GE, Fisher JN, et al. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab. 2008 May;93:1541–1552.
   PubMed Web of Science ®Google Scholar
• Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism. 2016 Apr;65:507–521.
   PubMed Web of Science ®Google Scholar
• Sharma PV, Jobanputra YB, Lewin K, et al. Diabetic ketoacidosis in patients with type 2 diabetes on sodium-glucose cotransporter-2 inhibitors - A case series. Rev Recent Clin Trials. 2018;13(2):156–160.
   PubMed Web of Science ®Google Scholar
• Vuk A, Baretic M, Osvatic MM, et al. Treatment of diabetic ketoacidosis associated with antipsychotic medication: literature review. J Clin Psychopharmacol. 2017 Oct;37(5):584–589.
   PubMed Web of Science ®Google Scholar
• Otiniano ME, Balasubramanyam A, Maldonado M. Presence of the metabolic syndrome distinguishes patients with ketosis-prone diabetes who have a type 2 diabetic phenotype. J Diabetes Complications. 2005 Nov–Dec;19:313–318.
   PubMed Web of Science ®Google Scholar
• Vellanki P, Smiley DD, Stefanovski D, et al. Randomized controlled study of metformin and sitagliptin on long term normoglycemia remission in African American patients with hyperglycemic crisis. Diabetes Care. 2016 Nov;39(11):1948–1955. Epub 2016 Aug 29.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003 Dec;144:5145–5148.
   PubMed Web of Science ®Google Scholar
• Andersen A, Lund A, Knop FK, et al. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018 May;14:390–403. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Popovic DS, Stokic E, Popovic SL. GLP-1 receptor agonists and type 1 diabetes - where do we stand? Curr Pharm Des. 2015;21:5292–5298.
   PubMed Web of Science ®Google Scholar
• Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev. 2009 Nov;5:266–275.
   PubMedGoogle Scholar
• Janzen KM, Steuber TD, Nisly SA. GLP-1 agonists in type 1 diabetes mellitus. Ann Pharmacother. 2016 Aug;50:656–665.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87:1409–1439.
   PubMed Web of Science ®Google Scholar
• Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017;13:315–321.
   PubMed Web of Science ®Google Scholar
• Patoulias D, Manafis A, Mitas C, et al. Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis; from pathophysiology to clinical practice. Cardiovasc Hematol Disord Drug Targets. 2018 Feb;18:139–146. Epub ahead of print.
   Google Scholar
• Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–1693.
   PubMed Web of Science ®Google Scholar
• Patel SG, Hsu JW, Jahoor F, et al. Pathogenesis of A⁻β⁺ ketosis-prone diabetes. Diabetes. 2013;62:912–922.
   PubMed Web of Science ®Google Scholar
• Umipierrez GE, Smiley D, Robalino G, et al. Lack of lipotoxicity effect on beta-cell dysfunction in ketosis-prone type 2 diabetes. Diabetes Care. 2010;33:626–631. pmid:20028938.
   PubMed Web of Science ®Google Scholar
• Mulukutla SN, Hsu JW, Gaba R, et al. Arginine metabolism is altered in adults with A-β + ketosis-prone diabetes. J Nutr. 2018 Feb;1(148):185–193.
   Google Scholar
• Sobngwi E 1, Gautier JF, Kevorkian JP, et al. High prevalence of glucose-6-phosphate dehydrogenase deficiency without gene mutation suggests a novel genetic mechanism predisposing to ketosis-prone diabetes. J Clin Endocrinol Metab. 2005 Aug;90(8):4446–4451. Epub 2005 May 24.
   PubMed Web of Science ®Google Scholar
• Maldonado MR, Otiniano ME, Cheema F, et al. Factors associated with insulin discontinuation in subjects with ketosis-prone diabetes but preserved beta-cell function. Diabet Med. 2005 Dec;22:1744–1750.
   PubMed Web of Science ®Google Scholar
• Sobngwi E, Vexiau P, Levy V, et al. Metabolic and immunogenetic prediction of long-term insulin remission in African patients with atypical diabetes. Diabet Med. 2002;19:832–835.
   PubMed Web of Science ®Google Scholar
• Hsin Yu E, Guo HR, Wu TJ. Factors associated with discontinuing insulin therapy after diabetic ketoacidosis in adult diabetic patients. Diabet Med. 2001 Nov;18:895–899.
   PubMed Web of Science ®Google Scholar
• Rasouli N, Elbein SC. Improved glycemic control in subjects with atypical diabetes results from restored insulin secretion, but not improved insulin sensitivity. J Clin Endocrinol Metab. 2004 Dec;89:6331–6335.
   PubMed Web of Science ®Google Scholar
• Piñero-Piloña A, Litonjua P, Aviles-Santa L, et al. Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience. Diabetes Care. 2001;24:1014.
   PubMed Web of Science ®Google Scholar
• Gaba R, Gambhire D, Uy N, et al. Factors associated with early relapse to insulin dependence in unprovoked A-β+ ketosis-prone diabetes. J Diabetes Complications. 2015;29:918–922.
   PubMed Web of Science ®Google Scholar